News

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...
Anselamimab is a type of monoclonal antibody that binds itself to specific targets in the amyloid deposits and helps break them down. The company has forecast peak sales potential of $1 billion to $3 ...
AstraZeneca PLC closed 21.60% below its 52-week high of £133.88, which the company achieved on September 3rd.
AstraZeneca PLC closed 20.36% short of its 52-week high of £133.88, which the company achieved on September 3rd.
The global HER2+ gastric cancer market is experiencing significant growth, driven by the rising incidence of gastric cancer and increased healthcare investments. HER2-positive gastric cancer, ...
AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...
Anal cancer is a rare yet increasing cancer linked primarily to high-risk HPV strains such as HPV-16 and HPV-18. Key risk factors include weakened immune systems, age over 50, and high-risk sexual ...
Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...
AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...
Genetically engineered bacteria have been created that can convert polyethylene terephthalate (PET), the polymer plastic ...
CRO Activity and Intel Report, featuring comprehensive insights into the contract research organization industry. Analyze trends by geography, therapeutic area, and development phase. Identify the ...
Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its Phase II trial. The strategic combination of IL-33 inhibitors with ...